<?xml version='1.0'?><!DOCTYPE Annotation PUBLIC "//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN_Modified" "../ModifiedGENIAtypes/Modified_GENIA_event_20.dtd"><Annotation annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=9616159" created="05/04/06" creator="Noriko Katsu"><PubmedArticleSet><PubmedArticle><MedlineCitation>
<PMID>9616159</PMID>
<Article>
<ArticleTitle>
<sentence id="S1">Inhibition of <term id="T1" lex="nuclear_factor_kappaB_activation" sem="Other"><term id="T2" lex="nuclear_factor_kappaB" sem="Protein_complex">nuclear factor kappaB</term> activation</term> attenuates <term id="T3" lex="apoptosis" sem="Other">apoptosis</term> resistance in <term id="T4" lex="lymphoid_cell" sem="Cell_natural">lymphoid cells</term>.</sentence>
<event KT="Other" id="E1">
<type class="Positive_regulation"/>
<theme idref="T2"/>
<clue>Inhibition of nuclear factor kappaB <clueType>activation</clueType> attenuates apoptosis resistance in lymphoid cells.</clue>
</event>
<event id="E2">
<type class="Negative_regulation"/>
<theme idref="E1"/>
<clue><clueType>Inhibition</clueType> <linkTheme>of</linkTheme> nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells.</clue>
</event>
<event id="E3">
<type class="Positive_regulation"/>
<theme idref="E36"/>
<cause idref="E2"/>
<clue>Inhibition of nuclear factor kappaB activation <clueType>attenuates</clueType> apoptosis <clueType>resistance</clueType> <linkTheme>in</linkTheme> lymphoid cells.</clue>
<comment>RESISTANCE</comment></event>
<event KT="Other" Polarity="Negative" id="E36">
<type class="Cellular_physiological_process"/>
<theme idref="T4"/>
<clue>Inhibition of nuclear factor kappaB activation attenuates <clueType>apoptosis</clueType> <cluePolarity>resistance</cluePolarity> in lymphoid cells.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2"><term id="T5" lex="death-inducing_ligand" sem="Protein_family_or_group">Death-inducing ligands</term> (<term id="T6" lex="DIL" sem="Protein_family_or_group">DILs</term>) such as <term id="T7" lex="tumor_necrosis_factor_alpha" sem="Protein_molecule">tumor necrosis factor alpha</term> (<term id="T8" lex="TNFalpha" sem="Protein_molecule">TNFalpha</term>) or the <term id="T9" lex="cytotoxic_drug" sem="Organic_compound_other">cytotoxic drug</term> <term id="T10" lex="doxorubicin" sem="Organic_compound_other">doxorubicin</term> have been shown to activate a <term id="T11" lex="nuclear_factor_kappaB_(NFkappaB)-dependent_program" sem="Other"><term id="T12" lex="nuclear_factor_kappaB" sem="Protein_complex">nuclear factor kappaB</term> (<term id="T13" lex="NFkappaB" sem="Protein_complex">NFkappaB</term>)-dependent <term id="A1" sem="Other">program</term></term> that may rescue <term id="A2" sem="Cell_natural">cells</term> from <term id="T14" lex="apoptosis" sem="Other">apoptosis</term> induction.</sentence>
<event KT="Other" id="E5">
<type class="Regulation"/>
<theme idref="A1"/>
<cause idref="T13"/>
<clue>Death-inducing ligands (DILs) such as tumor necrosis factor alpha (TNFalpha) or the cytotoxic drug doxorubicin have been shown to activate a nuclear factor kappaB (NFkappaB)-<clueType>dependent</clueType> program that may rescue cells from apoptosis induction.</clue>
</event>
<event KT="Analysis" Source="Other" id="E6">
<type class="Positive_regulation"/>
<theme idref="E5"/>
<cause idref="T8"/>
<clue><corefCause>Death-inducing ligands (DILs)</corefCause> such as tumor necrosis factor alpha (TNFalpha) or the cytotoxic drug doxorubicin <clueSource>have been</clueSource> <clueKT>shown</clueKT> to <clueType>activate</clueType> a nuclear factor kappaB (NFkappaB)-dependent program that may rescue cells from apoptosis induction.</clue>
</event>
<event KT="Analysis" Source="Other" id="E7">
<type class="Positive_regulation"/>
<theme idref="E5"/>
<cause idref="T10"/>
<clue>Death-inducing ligands (DILs) such as tumor necrosis factor alpha (TNFalpha) or the <corefCause>cytotoxic drug</corefCause> doxorubicin <clueSource>have been</clueSource> <clueKT>shown</clueKT> to <clueType>activate</clueType> a nuclear factor kappaB (NFkappaB)-dependent program that may rescue cells from apoptosis induction.</clue>
</event>
<event CL="L1" KT="Analysis" id="E8" uncertainty="probable">
<type class="Negative_regulation"/>
<theme idref="E9"/>
<cause idref="E5"/>
<clue>Death-inducing ligands (DILs) such as tumor necrosis factor alpha (TNFalpha) or the cytotoxic drug doxorubicin have been shown to activate a nuclear factor kappaB (NFkappaB)-dependent program that <clueKT><clueCL>may</clueCL></clueKT> <clueType>rescue</clueType> cells <linkTheme>from</linkTheme> apoptosis induction.</clue>
</event>
<event KT="Other" id="E9">
<type class="Positive_regulation"/>
<theme idref="T14"/>
<clue>Death-inducing ligands (DILs) such as tumor necrosis factor alpha (TNFalpha) or the cytotoxic drug doxorubicin have been shown to activate a nuclear factor kappaB (NFkappaB)-dependent program that may rescue <clueLoc>cells</clueLoc> from apoptosis <clueType>induction</clueType>.</clue>
</event>
<sentence id="S3">We demonstrate here that <term id="T15" lex="TRAIL" sem="Protein_molecule">TRAIL</term> (<term id="T16" lex="TNF-related_apoptosis-inducing_ligand" sem="Protein_molecule">TNF-related <term id="T17" lex="apoptosis" sem="Other">apoptosis</term>-inducing ligand</term>), a recently identified <term id="T18" lex="DIL" sem="Protein_family_or_group">DIL</term>, also activates <term id="T19" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> in lymphoid cell lines in a kinetic similar to <term id="T20" lex="TNFalpha" sem="Protein_molecule">TNFalpha</term>.</sentence>
<event KT="Analysis" id="E10">
<type class="Positive_regulation"/>
<theme idref="T19"/>
<cause idref="T15"/>
<clue>We <clueKT>demonstrate</clueKT> here that TRAIL (TNF-related apoptosis-inducing ligand), <corefCause>a recently identified DIL</corefCause>, also <clueType>activates</clueType> NFkappaB <clueLoc>in lymphoid cell lines</clueLoc> in a kinetic similar to TNFalpha.</clue>
</event>
<event KT="Analysis" id="E11">
<type class="Positive_regulation"/>
<theme idref="T19"/>
<cause idref="T20"/>
<clue>We <clueKT>demonstrate</clueKT> here that TRAIL (TNF-related apoptosis-inducing ligand), a recently identified DIL, also <clueType>activates</clueType> NFkappaB in lymphoid cell lines in a kinetic similar to TNFalpha.</clue>
</event>
<sentence id="S4"><term id="T21" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> activity is independent from <term id="T22" lex="FADD" sem="Protein_molecule">FADD</term>, <term id="T23" lex="caspases" sem="Protein_family_or_group">caspases</term>, and <term id="T24" lex="apoptosis_induction" sem="Other"><term id="T25" lex="apoptosis" sem="Other">apoptosis</term> induction</term>.</sentence>
<event KT="Other" id="E12">
<type class="Positive_regulation"/>
<theme idref="T25"/>
<clue>NFkappaB activity is independent from FADD, caspases, and apoptosis <clueType>induction</clueType>.</clue>
</event>
<event KT="Fact" Polarity="Negative" assertion="non-exist" id="E13">
<type class="Regulation"/>
<theme idref="T21"/>
<cause idref="T22"/>
<clue>NFkappaB activity is <clueType><cluePolarity>independent</cluePolarity></clueType> <linkCause>from</linkCause> FADD, caspases, and apoptosis induction.</clue>
</event>
<event KT="Fact" Polarity="Negative" assertion="non-exist" id="E14">
<type class="Regulation"/>
<theme idref="T21"/>
<cause idref="T23"/>
<clue>NFkappaB activity is <clueType><cluePolarity>independent</cluePolarity></clueType> <linkCause>from</linkCause> FADD, caspases, and apoptosis induction.</clue>
</event>
<event KT="Fact" Polarity="Negative" assertion="non-exist" id="E15">
<type class="Regulation"/>
<theme idref="T21"/>
<cause idref="E12"/>
<clue>NFkappaB activity is <clueType><cluePolarity>independent</cluePolarity></clueType> <linkCause>from</linkCause> FADD, caspases, and apoptosis induction.</clue>
</event>
<sentence id="S5">To study the influence of <term id="T26" lex="NFkappaB_activity" sem="Other"><term id="T27" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> activity</term> on <term id="T28" lex="apoptosis" sem="Other">apoptosis</term> mediated by <term id="T29" lex="TRAIL" sem="Protein_molecule">TRAIL</term>, CD95, <term id="T30" lex="TNFalpha" sem="Protein_molecule">TNFalpha</term>, or <term id="T31" lex="doxorubicin" sem="Organic_compound_other">doxorubicin</term>, <term id="T32" lex="NFkappaB_activation" sem="Other"><term id="T33" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> activation</term> was inhibited using the <term id="T34" lex="proteasome_inhibitor" sem="Organic_compound_other"><term id="T35" lex="proteasome" sem="Protein_complex">proteasome</term> inhibitor</term> <term id="T36" lex="N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal" sem="Organic_compound_other">N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal</term> or <term id="T37" lex="transient_overexpression" sem="Other">transient overexpression</term> of <term id="T38" lex="mutant_IkappaBalpha" sem="Protein_molecule">mutant IkappaBalpha</term>.</sentence>
<event KT="Investigation" id="E16" uncertainty="doubtful">
<type class="Regulation"/>
<theme idref="T28"/>
<cause idref="T26"/>
<clue><clueKT>To study</clueKT> the <clueType>influence</clueType> <linkCause>of</linkCause> NFkappaB activity <linkTheme>on</linkTheme> apoptosis mediated by TRAIL, CD95, TNFalpha, or doxorubicin, NFkappaB activation was inhibited using the proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal or transient overexpression of mutant IkappaBalpha.</clue>
</event>
<event KT="Other" id="E17" uncertainty="doubtful">
<type class="Positive_regulation"/>
<theme idref="E16"/>
<cause idref="T29"/>
<clue>To study the influence of NFkappaB activity on apoptosis <clueType>mediated</clueType> <linkCause>by</linkCause> TRAIL, CD95, TNFalpha, or doxorubicin, NFkappaB activation was inhibited using the proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal or transient overexpression of mutant IkappaBalpha.</clue>
</event>
<event KT="Other" id="E18" uncertainty="doubtful">
<type class="Positive_regulation"/>
<theme idref="E16"/>
<cause idref="T30"/>
<clue>To study the influence of NFkappaB activity on apoptosis <clueType>mediated</clueType> <linkCause>by</linkCause> TRAIL, CD95, TNFalpha, or doxorubicin, NFkappaB activation was inhibited using the proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal or transient overexpression of mutant IkappaBalpha.</clue>
</event>
<event KT="Other" id="E19" uncertainty="doubtful">
<type class="Positive_regulation"/>
<theme idref="E16"/>
<cause idref="T31"/>
<clue>To study the influence of NFkappaB activity on apoptosis <clueType>mediated</clueType> <linkCause>by</linkCause> TRAIL, CD95, TNFalpha, or doxorubicin, NFkappaB activation was inhibited using the proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal or transient overexpression of mutant IkappaBalpha.</clue>
</event>
<event KT="Other" id="E20">
<type class="Positive_regulation"/>
<theme idref="T33"/>
<clue>To study the influence of NFkappaB activity on apoptosis mediated by TRAIL, CD95, TNFalpha, or doxorubicin, NFkappaB <clueType>activation</clueType> was inhibited using the proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal or transient overexpression of mutant IkappaBalpha.</clue>
</event>
<event id="E21">
<type class="Negative_regulation"/>
<theme idref="E20"/>
<cause idref="T36"/>
<clue>To study the influence of NFkappaB activity on apoptosis mediated by TRAIL, CD95, TNFalpha, or doxorubicin, NFkappaB activation was <clueType>inhibited</clueType> <linkCause>using</linkCause> the proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal or transient overexpression of mutant IkappaBalpha.</clue>
</event>
<event id="E22">
<type class="Negative_regulation"/>
<theme idref="E20"/>
<cause idref="E35"/>
<clue>To study the influence of NFkappaB activity on apoptosis mediated by TRAIL, CD95, TNFalpha, or doxorubicin, NFkappaB activation was <clueType>inhibited</clueType> <linkCause>using</linkCause> the proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal or transient overexpression of mutant IkappaBalpha.</clue>
</event>
<event id="E23">
<type class="Gene_expression"/>
<theme idref="T38"/>
<clue>To study the influence of NFkappaB activity on apoptosis mediated by TRAIL, CD95, TNFalpha, or doxorubicin, NFkappaB activation was inhibited using the proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal or transient <clueType>overexpression</clueType> <linkTheme>of</linkTheme> mutant IkappaBalpha.</clue>
</event>
<event id="E35">
<type class="Positive_regulation"/>
<theme idref="E23"/>
<clue>To study the influence of NFkappaB activity on apoptosis mediated by TRAIL, CD95, TNFalpha, or doxorubicin, NFkappaB activation was inhibited using the proteasome inhibitor N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal or transient <clueType>overexpression</clueType> of mutant IkappaBalpha.</clue>
</event>
<sentence id="S6">Sensitivity for induction of <term id="T39" lex="apoptosis" sem="Other">apoptosis</term> was markedly increased by these treatments in <term id="T40" lex="apoptosis" sem="Other">apoptosis</term> sensitive <term id="T41" lex="cell_line" sem="Cell_cultured">cell lines</term>.</sentence>
<event id="E24">
<type class="Positive_regulation"/>
<theme idref="E4"/>
<clue>Sensitivity for <clueType>induction</clueType> <linkTheme>of</linkTheme> apoptosis was markedly increased by these treatments in apoptosis sensitive cell lines.</clue>
</event>
<event id="E4">
<type class="Cellular_physiological_process"/>
<theme idref="T41"/>
<clue>Sensitivity for induction of <clueType>apoptosis</clueType> was markedly increased by these treatments <linkTheme>in</linkTheme> apoptosis sensitive cell lines.</clue>
</event>
<event Manner="High" id="E25">
<type class="Positive_regulation"/>
<theme idref="E24"/>
<cause idref="E21"/>
<clue><clueType>Sensitivity</clueType> for induction of apoptosis was <clueManner>markedly</clueManner> <clueType>increased</clueType> <linkCause>by</linkCause> <corefCause>these treatments</corefCause> in apoptosis sensitive cell lines.</clue>
<comment>SENSITIVITY</comment></event>
<event Manner="High" id="E26">
<type class="Positive_regulation"/>
<theme idref="E24"/>
<cause idref="E22"/>
<clue><clueType>Sensitivity</clueType> for induction of apoptosis was <clueManner>markedly</clueManner> <clueType>increased</clueType> <linkCause>by</linkCause> <corefCause>these treatments</corefCause> in apoptosis sensitive cell lines.</clue>
</event>
<sentence id="S7">Moreover, both in <term id="A30" sem="Cell_cultured">cell lines</term> and in <term id="A31" sem="Cell_cultured">primary leukemia cells</term> that are resistant towards induction of <term id="T42" lex="apoptosis" sem="Other">apoptosis</term> by <term id="T43" lex="DIL" sem="Protein_family_or_group">DILs</term> and <term id="T44" lex="doxorubicin" sem="Organic_compound_other">doxorubicin</term>, antagonization of <term id="T45" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> activity partially restored <term id="T46" lex="apoptosis_sensitivity" sem="Other"><term id="T47" lex="apoptosis" sem="Other">apoptosis</term> sensitivity</term>.</sentence>
<event KT="Fact" Polarity="Negative" assertion="non-exist" id="E27">
<type class="Positive_regulation"/>
<theme idref="E37"/>
<cause idref="T43"/>
<clue>Moreover, both in cell lines and in primary leukemia cells that are <clueType><cluePolarity>resistant</cluePolarity></clueType> towards <clueType>induction</clueType> <linkTheme>of</linkTheme> apoptosis <linkCause>by</linkCause> DILs and doxorubicin, antagonization of NFkappaB activity partially restored apoptosis sensitivity.</clue>
<comment>RESISTANCE</comment></event>
<event KT="Fact" Polarity="Negative" assertion="non-exist" id="E28">
<type class="Positive_regulation"/>
<theme idref="E38"/>
<cause idref="T44"/>
<clue>Moreover, both in cell lines and in primary leukemia cells that are <clueType><cluePolarity>resistant</cluePolarity></clueType> towards <clueType>induction</clueType> <linkTheme>of</linkTheme> apoptosis <linkCause>by</linkCause> DILs and doxorubicin, antagonization of NFkappaB activity partially restored apoptosis sensitivity.</clue>
</event>
<event KT="Other" id="E37">
<type class="Cellular_physiological_process"/>
<theme idref="A30"/>
<clue>Moreover, both <linkTheme>in</linkTheme> cell lines and in primary leukemia cells that are resistant towards induction of <clueType>apoptosis</clueType> by DILs and doxorubicin, antagonization of NFkappaB activity partially restored apoptosis sensitivity.</clue>
</event>
<event KT="Other" id="E38">
<type class="Cellular_physiological_process"/>
<theme idref="A31"/>
<clue>Moreover, both <linkTheme>in</linkTheme> cell lines and in primary leukemia cells that are resistant towards induction of <clueType>apoptosis</clueType> by DILs and doxorubicin, antagonization of NFkappaB activity partially restored apoptosis sensitivity.</clue>
</event>
<event id="E29">
<type class="Negative_regulation"/>
<theme idref="T45"/>
<clue>Moreover, both in cell lines and in primary leukemia cells that are resistant towards induction of apoptosis by DILs and doxorubicin, <clueType>antagonization</clueType> <linkTheme>of</linkTheme> NFkappaB activity partially restored apoptosis sensitivity.</clue>
</event>
<event assertion="non-exist" id="E30">
<type class="Negative_regulation"/>
<theme idref="E37"/>
<cause idref="E29"/>
<clue>Moreover, both in cell lines and in primary leukemia cells that are resistant towards induction of apoptosis by DILs and doxorubicin, antagonization of NFkappaB activity partially <clueType>restored</clueType> <corefTheme>apoptosis</corefTheme> <clueType>sensitivity</clueType>.</clue>
<comment>SENSITIVITY</comment></event>
<event id="E39">
<type class="Negative_regulation"/>
<theme idref="E38"/>
<cause idref="E29"/>
<clue>Moreover, both in cell lines and in primary leukemia cells that are resistant towards induction of apoptosis by DILs and doxorubicin, antagonization of NFkappaB activity partially <clueType>restored</clueType> <corefTheme>apoptosis</corefTheme> <clueType>sensitivity</clueType>.</clue>
<comment>SENSITIVITY</comment></event>
<sentence id="S8">These data suggest that inhibition of <term id="T48" lex="NFkappaB_activation" sem="Other"><term id="T49" lex="NFkappaB" sem="Protein_complex">NFkappaB</term> activation</term> may provide a molecular approach to increase <term id="A3" sem="Other"><term id="T50" lex="apoptosis" sem="Other">apoptosis</term> sensitivity</term> in <term id="T51" lex="anticancer_treatment" sem="Other">anticancer treatment</term>.</sentence>
<event KT="Other" id="E31">
<type class="Positive_regulation"/>
<theme idref="T49"/>
<clue>These data suggest that inhibition of NFkappaB <clueType>activation</clueType> may provide a molecular approach to increase apoptosis sensitivity in anticancer treatment.</clue>
</event>
<event KT="Other" id="E32">
<type class="Negative_regulation"/>
<theme idref="E31"/>
<clue>These data suggest that <clueType>inhibition</clueType> <linkTheme>of</linkTheme> NFkappaB activation may provide a molecular approach to increase apoptosis sensitivity in anticancer treatment.</clue>
</event>
<event KT="Other" id="E33">
<type class="Positive_regulation"/>
<theme idref="A3"/>
<clue>These data suggest that inhibition of NFkappaB activation may provide a molecular approach to <clueType>increase</clueType> apoptosis sensitivity in anticancer treatment.</clue>
</event>
<event CL="L1" KT="Analysis" id="E34" uncertainty="probable">
<type class="Regulation"/>
<theme idref="E33"/>
<cause idref="E31"/>
<clue>These data <clueKT>suggest</clueKT> that inhibition of NFkappaB activation <clueCL>may</clueCL> <clueType>provide a molecular approach</clueType> <linkTheme>to</linkTheme> increase apoptosis sensitivity in anticancer treatment.</clue>
</event>
</AbstractText>
</Abstract></Article></MedlineCitation></PubmedArticle></PubmedArticleSet></Annotation>
